NewLimit
NewLimit is pushing the boundaries of biotechnology research with a bold vision: to extend healthy human lifespan. This is not just theoretical; they are actively seeking talented individuals to join their focused team of 36. If you are passionate about revolutionizing the way we understand and combat aging, NewLimit presents a unique opportunity to contribute to a groundbreaking field with the potential for massive impact. Currently, they are looking for skilled professionals to immediately contribute to their research efforts. Open roles include Senior Research Associates in Immunology and Single Cell Technology, as well as a Senior/Research Associate in Drug Product Development. These positions offer the chance to work alongside leading experts, utilizing cutting-edge technologies to tackle some of the most complex biological challenges. At NewLimit, you'll be immersed in a dynamic and collaborative environment, driving discovery and contributing to the future of longevity research.
About the Company
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Quick Facts
Open Positions
3<h1>About NewLimit</h1> <p>NewLimit is a biotechnology company working to radically extend human healthspan. We are developing medicines to treat age-related diseases by reprogramming the epigenome—a ...
<h1>About NewLimit</h1> <p>NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a ...
<h2>About NewLimit</h2> <p>NewLimit is a biotechnology company working to radically extend human healthspan. We are developing medicines to treat age-related diseases by reprogramming the epigenome—a ...